Managing Partner
- sander.slootweg@forbion.com
- Download vCard 
Sander is a highly experienced life sciences investor, having been involved in 17 investments in this sector. His specialties involve deal execution (for new investments as well as exits via M&A and IPO’s), as well as helping his companies focus on economically viable business models.
Sander’s key accomplishments include: i) the sale of GlycArt to Roche in 2005 for CHF 235 million, as a member of the M&A committee and as a liaison with Investment Bank, ii) closing of a USD 35 million non-dilutive licensing deal for Argos Therapeutics, iii) merger of Ubisys with Introgene, creating Crucell, iv) financing of Korean acquisition of Rhein Biotech, v) reverse take over of Argenta by Etiologics and vi) merger of AM Pharma and PharmAAware.
After joining ABN AMRO Private Equity in 1999, Sander acted as co-founder of ABN AMRO Capital Life Sciences (AAC LS) in 2000. His investments at AAC LS included the acquisition financing of Green Cross Vaccine Corp (Korea) by Rhein Biotech N.V, the Series A rounds of AM Pharma B.V. and Amsterdam Molecular Therapeutics (AMT) B.V., and the Series B round of Xention Discovery Ltd. In all other deals, some of which were co-led by ABN AMRO Capital, Sander took an active role. He currently serves on the boards of Alantos Pharmaceuticals Inc, Argenta Discovery Ltd, Xention Discovery, Bioceros B.V. and AMT B.V.
Sander has also served on the boards of AM Pharma B.V., PharmAAware B.V. (now merged with AM Pharma), Cambridge Drug Discovery Ltd (now Biofocus Plc), Etiologics Ltd (now Argenta), Pieris Proteolab AG, Impella CardioSystems AG and Cilian AG. He has also represented ABN AMRO Capital’s interests in the boards of Argos Therapeutics Inc (formerly Merix Biosciences Inc), Ardana Plc and GlycArt AG.
Prior to this, Sander was at the Financial Institutions Relationship Management Group, which he joined in 1994 as an assistant global relationship manager for financial institutions in the Americas. From 1997-1999 he was responsible for all Financial Institutions in Argentina, Brazil and Chile, operating out of the Miami office.
Sander began his career at ABN AMRO in 1993 as a management trainee for the Investment Banking operations. After completing his traineeship, he was briefly assigned to the Equity Syndicate Desk, part of the Equity Capital Markets Group. Here he was involved in the largest Dutch IPO to date: the privatization of KPN, the Dutch national telephone company.
Sander has degrees in Business Administration (Nijenrode University, 1989) and Business Economics (Free University of Amsterdam, 1992). He wrote his graduation thesis on different ways of applying complex valuation models in M&A transactions.
